The association of metabolic syndrome risk factors with serum high-molecular weight adiponectin and urinary metabolites among the orang asli in Malaysia by Ashari, Lydiatul Shima
  
THE ASSOCIATION OF METABOLIC 
SYNDROME RISK FACTORS WITH SERUM 
HIGH-MOLECULAR WEIGHT ADIPONECTIN 
AND URINARY METABOLITES AMONG THE 
ORANG ASLI IN MALAYSIA 
 
 
 
 
 
 
 
 
LYDIATUL SHIMA BINTI ASHARI 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
 
2016 
  
THE ASSOCIATION OF METABOLIC SYNDROME RISK FACTORS 
WITH SERUM HIGH-MOLECULAR WEIGHT ADIPONECTIN AND 
URINARY METABOLITES AMONG THE ORANG ASLI IN MALAYSIA 
 
 
 
 
by 
 
 
 
 
 
 
 
 
LYDIATUL SHIMA BINTI ASHARI 
 
 
 
 
 
 
 
 
Thesis submitted in fulfillment of the requirements 
for the degree of  
Master of Science 
 
 
 
 
 August 2016 
ii 
 
ACKNOWLEDGEMENT 
 
In the name of Allah, The Most Gracious, The Most Merciful. Alhamdulillah, I  
praise and thank Allah SWT for giving me strength, courage, and endurance to 
complete this thesis. 
 
My deepest gratitude goes to my supervisor Assoc. Prof. Dr. Hamid Jan Bin 
Jan Mohamed and co-supervisors, Prof. Dr. Teh Lay Kek and Assoc. Prof. Dr. 
Zafarina Binti Zainuddin for constructive academic supervision and enthusiastic 
encouragement throughout the research study. Their valuable ideas, constructive 
recommendations, and professional guidance have enhanced this thesis.  
 
I would like to express gratitude to Ministry of Higher Education (MOHE) 
and Universiti Sains Malaysia (USM) for my sponsorship through MyBrain15 
programme and USM Fellowship Scheme, respectively. Also thank you to MOHE 
for funding my research study through the Long Term Research Grant Scheme 
(LRGS) (304/PPSK/6150116/U132). I am grateful to Orang Asli (OA) population, 
Orang Asli Development Department (JAKOA), and Faculty of Art and Design 
(FSSR), Universiti Teknologi MARA (UiTM) for their cooperation. Many thanks to 
Central Research Lab (CRL), School of Medical Sciences, USM, and Integrative 
Pharmacogenomics Institute (iPROMISE), UiTM for providing help, guidance, and 
facilities for high-molecular weight (HMW) adiponectin and metabolomics analysis. 
 
My sincere thanks are also extended to my colleagues, Norliyana Binti Aris, 
Tasnim Binti Abdul Razak, Ainaa Almardhiyah Binti Abd Rashid, Nur Nadia Binti 
iii 
 
Mohamed, Syarifah Nany Rahayu Karmilla Binti Syed Hassan, Nurul Hidayah Binti 
Nazri, and Zunura’in Binti Zahali who give the never ending support and motivation 
for me to achieve all the objectives of the project.  
 
I would like to convey my special appreciation to my beloved family 
especially my father, Ashari Bin Che Mat and my mother, Naimah Binti Mat Nor for 
their prayers, undivided supports, and understanding during accomplishment of this 
thesis. Last but not least, warmest appreciation to all those who have helped me 
directly or indirectly in the realization and successfulness of the thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
TABLE OF CONTENT 
 
ACKNOWLEDGEMENT ........................................................................................... ii 
TABLE OF CONTENT .............................................................................................. iv 
LIST OF TABLES ...................................................................................................... ix 
LIST OF FIGURES ..................................................................................................... x 
LIST OF SYMBOLS, ABBREVIATIONS, AND ACRONYMNS ........................... xi 
ABSTRAK ............................................................................................................... xvii 
ABSTRACT .............................................................................................................. xix 
CHAPTER 1 INTRODUCTION ................................................................................. 1 
1.1 Background of the study ..................................................................................... 1 
1.2 Rationale of the study ......................................................................................... 4 
1.3 Significance of the study .................................................................................... 6 
1.4 Objectives ........................................................................................................... 7 
1.4.1 General objective....................................................................................... 7 
1.4.2 Specific objectives..................................................................................... 7 
1.5 Research questions.............................................................................................. 7 
1.6 Null hypotheses .................................................................................................. 8 
1.7 Conceptual framework........................................................................................ 8 
CHAPTER 2 LITERATURE REVIEW .................................................................... 10 
2.1 Orang Asli ......................................................................................................... 10 
2.2 Nutritional status ............................................................................................... 14 
2.2.1 Metabolic syndrome ................................................................................ 16 
2.3 Adipokines ........................................................................................................ 20 
2.3.1 Adiponectin ............................................................................................. 23 
v 
 
2.3.1 (a) Structure and circulating levels .............................................. 24 
2.3.1 (b) Receptors ................................................................................ 25 
2.3.1 (c) Clinical features ...................................................................... 26 
2.4 Metabolomics ................................................................................................... 27 
2.4.1 Analytical tools ....................................................................................... 27 
2.4.2 Biofluid.................................................................................................... 28 
2.4.3 Applications ............................................................................................ 29 
2.5 Associations of metabolic syndrome (MetS) risk factors, high-molecular 
weight (HMW) adiponectin, and urinary metabolites ...................................... 32 
CHAPTER 3 MATERIALS AND METHODS ......................................................... 33 
3.1 Study design and area ....................................................................................... 33 
3.2 Study population ............................................................................................... 35 
3.3 Sampling methods ............................................................................................ 35 
3.4 Sample size ....................................................................................................... 36 
3.5 Ethical considerations and research permission ............................................... 40 
3.6 Data collection .................................................................................................. 42 
3.6.1 Structured questionnaire .......................................................................... 42 
3.6.2 Anthropometric measurement ................................................................. 42 
3.6.2 (a) Height ..................................................................................... 43 
3.6.2 (b) Body weight ............................................................................ 44 
3.6.2 (c) Body mass index (BMI).......................................................... 44 
3.6.2 (d) Waist circumference (WC) ..................................................... 44 
3.6.2 (e) Body fat .................................................................................. 45 
3.6.3 Blood pressure ......................................................................................... 47 
3.6.4 Blood sample collection .......................................................................... 48 
3.6.5 Urine sample collection ........................................................................... 48 
3.7 Principle and procedure for biochemical analysis ............................................ 49 
3.7.1 Analysis for triglyceride (TG) ................................................................. 50 
vi 
 
3.7.1 (a)  Principle ................................................................................... 50 
3.7.1 (b)  Procedure ................................................................................. 51 
3.7.2 Analysis for high-density lipoprotein cholesterol (HDL-C) ................... 51 
3.7.2 (a)  Principle ................................................................................... 51 
3.7.2 (b)  Procedure ................................................................................. 52 
3.7.3  Analysis for glucose ................................................................................ 52 
3.7.3 (a)  Principle ................................................................................... 52 
3.7.3 (b) Procedure ................................................................................ 53 
3.7.4 High-molecular weight (HMW) adiponection ........................................ 53 
3.7.4 (a) Principle .................................................................................. 53 
3.7.4 (b) Procedure ................................................................................ 54 
3.8 Metabolic syndrome (MetS) definition ............................................................ 56 
3.9 Study subjects for metabolomics analysis ........................................................ 56 
3.10 Urine sample preparation .................................................................................. 56 
3.11 LC-QTOF-MS analysis .................................................................................... 57 
3.12 Data processing and data analysis .................................................................... 58 
3.13 ROC Curve Explorer & Tester (ROCCET) ...................................................... 61 
3.13.1 Data upload and processing ................................................................ 61 
3.13.2 Data analysis (classical univariate ROC curve analyses) ................... 61 
3.14 Statistical analyses ............................................................................................ 61 
CHAPTER 4 RESULTS ............................................................................................ 64 
4.1 Socio-demographic characteristics ................................................................... 64 
4.2 Anthropometric profiles.................................................................................... 66 
4.3 Biochemical and physical profiles .................................................................... 67 
4.4 Metabolic syndrome (MetS) prevalence ........................................................... 68 
4.5 Prevalence of individual risk factors of metabolic syndrome (MetS) .............. 69 
4.6 Baseline characteristics for metabolomics study .............................................. 71 
4.7 Principal component analysis (PCA) ................................................................ 72 
vii 
 
4.8 Heat-map analysis ............................................................................................. 72 
4.9 Metabolite profiling .......................................................................................... 74 
4.10 Potential urinary metabolite biomarkers ........................................................... 74 
4.11 Correlations of metabolic syndrome (MetS) risk factors and high-
molecular weight (HMW) adiponectin ............................................................. 78 
4.12 Correlation of urinary metabolites with metabolic syndrome (MetS) risk 
factors and high-molecular weight (HMW) adiponectin .................................. 78 
4.13 Associations of metabolic syndrome (MetS) risk factors with high-
molecular weight (HMW) adiponectin ............................................................. 81 
4.14 Associations of metabolic syndrome (MetS) risk factors with urinary 
metabolite ......................................................................................................... 82 
4.15 Associations of high-molecular weight (HMW) adiponectin with urinary 
metabolite ......................................................................................................... 84 
CHAPTER 5 DISCUSSIONS .................................................................................... 85 
5.1 Nutritional status of Orang Asli (OA) populations........................................... 85 
5.2 Metabolic syndrome (MetS) of Orang Asli (OA)............................................. 87 
5.2.1 Prevalence of metabolic syndrome (MetS) ............................................. 87 
5.2.2 Prevalence of individual risk factors of metabolic syndrome (MetS) ..... 90 
5.3 High-molecular weight (HWM) adiponectin concentration ............................. 91 
5.4 Metabolites profiling and biomarkers discovery .............................................. 92 
5.4.1 Fatty acids (FAs) ..................................................................................... 92 
5.4.2 Amino Acid (AA).................................................................................... 95 
5.4.3 Bile Acids (BAs) ..................................................................................... 96 
5.5 Associations of metabolic syndrome (MetS) risk factors with high-
molecular weight (HMW) adiponectin ............................................................. 97 
5.5.1 Associations of waist circumference (WC) with high-molecular 
weight (HMW) adiponectin .................................................................... 98 
5.5.2 Associations of sex and age with high-molecular weight (HMW) 
adiponectin ............................................................................................ 102 
viii 
 
5.6 Associations of metabolic syndrome (MetS) risk factors with urinary 
metabolites ...................................................................................................... 103 
5.6.1 Associations of metabolic syndrome (MetS) risk factors with 
urinary fatty acids (FAs) ....................................................................... 103 
5.6.2 Associations of metabolic syndrome (MetS) risk factors with 
urinary amino acid (AA) ....................................................................... 106 
5.7 Associations of high-molecular weight (HMW) adiponectin with urinary 
metabolites ...................................................................................................... 107 
5.7.1 Associations of high-molecular weight (HMW) adiponectin with 
urinary fatty acid (FA)........................................................................... 108 
5.7.2 Associations of high-molecular weight (HMW) adiponectin with 
urinary amino acid (AA) ....................................................................... 111 
5.8 Strenghts of study ........................................................................................... 111 
5.9  Limitations of study ........................................................................................ 112 
5.10 Recommendations........................................................................................... 113 
CHAPTER 6 CONCLUSION .................................................................................. 114 
REFERENCES ......................................................................................................... 116 
APPENDICES ......................................................................................................... 146 
Appendix 1: Ethical approval letter (Universiti Sains Malaysia) ............................ 146 
Appendix 2: Ethical approval letter (Universiti Teknologi MARA) ....................... 148 
Appendix 3: Orang Asli Development Department (JAKOA) letter ....................... 152 
Appendix 4: Orang Asli Development Department (JAKOA) letter ....................... 155 
Appendix 5: Written informed consent .................................................................... 158 
Appendix 6: Questionnaires ..................................................................................... 164 
Appendix 7: Coefficients of variability (CV) .......................................................... 169 
LIST OF PUBLICATIONS ..................................................................................... 170 
ix 
 
LIST OF TABLES 
 
        Page 
Table 2.1 Population distribution and characteristics of the study 
population of Orang Asli subtribe ...................................................... 11 
Table 2.2 Classification of Orang Asli village ................................................... 14 
Table 2.3 Ethnic-specific cut points for waist circumference by 
International Diabetes Federation organization.................................. 18 
Table 2.4 Definitions of metabolic syndrome by organization .......................... 19 
Table 2.5 Current recommended cut points for waist circumference by  
organization ........................................................................................ 20 
Table 3.1 Sample size calculations for specific objectives ................................ 38 
Table 3.2 Body fat percentage classification ...................................................... 47 
Table 3.3 Visceral fat rating classification ......................................................... 47 
Table 4.1 Socio-demographic characteristics of respondentsa ........................... 65 
Table 4.2 Anthropometric measurements of the respondents (n=185)
a,b
 ........... 67 
Table 4.3 Biochemical and physical characteristics of respondents 
(n=185)
a,b
 ............................................................................................ 68 
Table 4.4 Prevalence of metabolic syndrome among respondents: by sex, 
age, and subtribe
 
(n=185)
a
 .................................................................. 69 
Table 4.5 Prevalence of individual risk factors of metabolic syndrome 
among respondents: overall and by sex
 
(n=185)
a,b
 ............................. 70 
Table 4.6 Prevalence of individual risk factors of metabolic syndrome 
among respondents: by subtribe
 
(n=185)
a,b
 ........................................ 70 
Table 4.7 Baseline characteristics of respondents (n=27)
a
 ................................. 71 
Table 4.8 Lists of differentially expressed urine metabolites among the 
metabolic syndrome and control ........................................................ 75 
Table 4.9 List of potential urinary metabolite biomarkers ranked based on 
area under ROC curve (AUROC) ....................................................... 77 
Table 4.10 Correlation between metabolic syndrome risk factors and high-
molecular weight adiponectin (n=185)
a
 ............................................. 78 
Table 4.11 Correlation between urinary metabolites with metabolic 
syndrome risk factors and high-molecular weight adiponectin 
(n=27) ................................................................................................. 80 
Table 4.12 Associated factors of high-molecular weight adiponectin 
(n=185)
a
 .............................................................................................. 82 
Table 4.13 Associated factors of 3-ethyl-3-methyl-tridecanoic acid (n=27)........ 83 
Table 4.14 Associated factors of 3-ethyl-3-methyl-tridecanoic acid (n=27)........ 84 
x 
 
LIST OF FIGURES 
 
        Page 
Figure 1.1 Conceptual framework of the study ..................................................... 9 
Figure 2.1   Distribution map of the Orang Asli subtribes in Peninsular 
Malaysia ............................................................................................. 13 
Figure 2.2 Different type of adipokines released by the adipose tissue that 
associated with obesity and metabolic syndrome ............................... 22 
Figure 2.3 Domains and structure of adiponectin ................................................ 25 
Figure 2.4 General procedures for diagnosis and biomarker discovery in 
metabolomics ...................................................................................... 31 
Figure 3.1 Map of Peninsular Malaysia indicating sampling sites ...................... 34 
Figure 3.2 Flow chart of the study ....................................................................... 41 
Figure 3.3 Mechanical measuring tape seca 206 ................................................. 43 
Figure 3.4 Standing height position ..................................................................... 43 
Figure 3.5 Measuring tape ................................................................................... 45 
Figure 3.6 Measuring tape position for waist circumference .............................. 45 
Figure 3.7 Body composition analyzer Tanita SC-330 ........................................ 46 
Figure 3.8 Automatic blood pressure monitor ..................................................... 48 
Figure 4.1 Principal component analysis of metabolic syndrome (blue) and 
control (red) ........................................................................................ 72 
Figure 5.1 Mechanism underlying obesity-related insulin resistance ................ 105 
Figure 5.2 The regulation of adiponectin production and its effects on 
glucose and lipid metabolism ........................................................... 109 
 xi 
 
LIST OF SYMBOLS, ABBREVIATIONS, AND ACRONYMNS 
 
AA    Amino acid 
AAs    Amino acids   
Ab    Antibody  
ACC   Acetyl-coenzyme A carboxylase  
ACE   Angiotensinogen-converting enzyme  
ACN    Acetonitrile  
ACR   Albumin/creatinine ratio 
AdipoR1  Adiponectin receptor 1 
AdipoR2  Adiponectin receptor 2  
ADP    Adenosine 5′-diphosphate  
AHA/NHLBI  American Heart Association/National Heart, Lung, and Blood 
Institute 
AMPK   Adenosine monophosphate-activated protein kinase  
ANGPTL2  Angiopoietin-like protein 2 
ATP    Adenosine 5′-triphosphate 
ATP III  Adult Treatment Panel III 
AUC   Area under the curve 
AUROC   Area under ROC curve  
BA   Bile acid 
BAs    Bile acids  
BAT   Brown adipose tissue 
BIA    Bioelectrical impedance analysis  
BMI   Body mass index 
 xii 
 
BUN    Blood urea nitrogen  
CAD    Coronary artery disease  
cDNA   Complementary deoxyribonucleic acid  
CI   Confidence interval 
CPDRL   Centre for Pathology Diagnostic and Research Laboratories  
CRP   C-reactive protein 
CV    Coefficients of variability 
CVD    Cardiovascular disease 
CVDs    Cardiovascular diseases 
DDAH   Dimethylarginine dimethylaminohydrolase  
DXA    Dual energy x-ray absorptiometry   
EGP   Endogenous glucose production 
ELISA   Enzyme-linked immunosorbent assay  
ESI    Electrospray ionization  
FA    Fatty acid 
FAs   Fatty acids   
FFA   Free fatty acid 
FFAs    Free fatty acids 
FCR    Fractional catabolic rate  
FDR    False discovery rate  
FFA    Free fatty acid  
G6PDH  Glucose-6-phosphate dehydrogenase  
GIR    Glucose infusion rate  
GLUT4  Glucose transporter 4  
H2O2   Hydrogen peroxide  
 xiii 
 
H2SO4   Sulfuric acid 
HbA1c   Glycated hemoglobin  
HDL   High-density lipoprotein 
 
HDL-C  High-density lipoprotein cholesterol 
HK    Hexokinase  
HMDB   Human Metabolome Database  
HMW   High-molecular weight  
HOMA-IR  Homeostasis model assessment of insulin resistance  
HRP   Horse radish peroxidase  
hs-CRP   High-sensitivity C-reactive protein  
HSD    Honestly significant difference 
HSL    Hormone-sensitive lipase 
IAF    Intra-abdominal fat 
IASO   International Association for the study of Obesity 
IDF   International Diabetes Federation 
IFG   Impaired fasting glucose  
IGT    Impaired glucose tolerance 
IL-6   Interleukin-6  
IOTF   International Obesity Task Force  
IPH   Institute for Public Health 
IQR   Interquartile range 
IR   Insulin resistance  
KEGG   Kyoto Encyclopedia of Genes and Genomes  
L/A    Leptin to adiponectin  
LC    Liquid chromatography 
 xiv 
 
LCFA   Long chain fatty acids  
LC-MS   Liquid chromatography-mass spectrometry  
LC-QTOF-MS  Liquid chromatography-hybrid quadrupole time-of-flight  
mass spectrometry  
LDL   Low-density lipoprotein  
LDL-C  Low-density lipoprotein cholesterol  
LIPID MAPS   Lipid Metabolites and Pathways Strategy  
LMW   Low-molecular weight  
LPL    Lipoprotein lipase  
MCFA   Medium chain fatty acids  
MCP-1   Monocyte chemoattractant protein-1 
MetS   Metabolic syndrome  
MFE   Molecular Feature Extraction  
MMW   Middle-molecular weight  
MRI    Magnetic resonance imaging  
NEFA    Non-esterified fatty acid   
NCEP ATP III National Cholesterol Education Program Adult Treatment 
Panel III 
NGT    Normal glucose tolerant  
NHANES  National Health and Nutrition Examination Survey  
NHMS   National Health and Morbidity Survey  
OA Orang Asli 
OPD    O-phenylenediamine 
PAD    Peripheral artery disease  
PAI-1   Plasminogen activator inhibitor-1  
 xv 
 
PCA    Principal component analysis 
PEG   Polyethylene glycol  
PMI    Planned myocardial infarction   
POD    Peroxidase  
PPAR   Peroxisome proliferator activated receptor  
QC   Quality control  
QTOF    Quadrupole-time-of-flight  
RBP4   Retinol binding protein 4  
Rf   Relative flotation index 
 
ROCCET  ROC Curve Explorer & Tester 
SAA   Serum amyloid A  
SAT    Subcutaneous adipose tissue  
SCAT    Subcutaneous abdominal fat   
SCFA    Small chain fatty acids  
SD Standard deviation 
SPSS Statistical Package for the Social Sciences 
SUA Serum uric acid  
T2DM   Type 2 diabetes mellitus 
TAG    Triacylglycerol  
TC   Total cholesterol  
TCA    Tricarboxylic acid   
TG    Triglyceride 
THM   Tetrahydrometabolites  
TNF-α   Tumor necrosis factor-α  
UAE   Urinary albumin excretion  
 xvi 
 
UiTM   Universiti Teknologi MARA 
USM   University Sains Malaysia 
UPLC-qTOF-MS Ultra performance liquid chromatography coupled to 
electrospray ionization quadrupole time of flight mass 
spectrometry 
VAT  Visceral abdominal fat  
VAT  Visceral adipose tissue  
VEGF Vascular endothelial growth factor  
VLCFA  Very long chain fatty acids  
VLDL   Very low density lipoprotein  
VLDL B  Very low density lipoprotein B 
VLDL–TAG   Very low density lipoprotein triacylglycerols 
VIF  Variance inflation factor  
WAT White adipose tissue  
WC Waist circumference 
WHO World Health Organization  
WHR    Waist hip ratio  
WHtR    Waist height ratio  
 
  
 xvii 
 
PERKAITAN FAKTOR-FAKTOR RISIKO SINDROM METABOLIK 
DENGAN ADIPONEKTIN BERAT MOLEKUL TINGGI SERUM DAN 
METABOLIT-METABOLIT URIN DALAM KALANGAN ORANG ASLI DI 
MALAYSIA 
 
ABSTRAK 
 
Orang Asli (OA) merupakan orang asal di Semenanjung Malaysia. Secara 
keseluruhan, terdapat lapan belas suku kaum OA yang dikategorikan di bawah tiga 
kaum utama iaitu Senoi, Melayu Proto, dan Negrito. Perkaitan faktor-faktor risiko 
sindrom metabolik dengan adiponektin berat molekul tinggi serum dan metabolit-
metabolit urin dalam kalangan OA jarang dilaporkan. Tujuan kajian ini adalah untuk 
menentukan perkaitan antara faktor-faktor risiko sindrom metabolik dengan 
adiponektin berat molekul tinggi serum dan metabolit-metabolit urin dalam kalangan 
OA di Semenanjung Malaysia. Kaedah kajian yang dijalankan adalah keratan rentas 
dan pemilihan lokasi kajian adalah menerusi kaedah persampelan rawak mudah. 
Enam lokasi suku kaum OA telah dipilih iaitu Che Wong, Kensiu, Semai, Orang 
Kanaq, Lanoh, dan Bateq. Kaedah persampelan bertujuan dan bola salji telah 
digunakan untuk memilih 185 responden yang berumur 18 tahun dan ke atas. Ukuran 
berat, ketinggian, ukur lilit pinggang, dan tekanan darah direkodkan. Sampel darah 
subjek yang berpuasa semalaman telah dianalisis untuk mengkaji profil lipid, glukosa 
plasma, dan adiponektin berat molekul tinggi serum manakala sampel urin untuk 
mengkaji profil metabolit dengan menggunakan pendekatan metabolomiks. Secara 
keseluruhan prevalens sindrom metabolik adalah 29.7% (55/185). Prevalens sindrom 
metabolik secara signifikan lebih tinggi dalam kalangan responden wanita (36.2%) 
 xviii 
 
berbanding lelaki (21.3%). Sindrom metabolik juga adalah lebih tinggi di kalangan 
suku kaum yang tinggal di kawasan pinggir bandar iaitu Orang Kanaq (81.8%) dan 
Kensiu (36.4%) dan lebih rendah di kawasan pedalaman iaitu Semai (23.8%) dan 
Bateq (8.0%) (p<0.001). Responden wanita dilaporkan secara signifikan mempunyai 
kadar peningkatan ukur lilit pinggang (45.7% vs. 2.5%, p<0.001) dan penurunan aras 
lipoprotein berdensiti tinggi (69.5% vs. 31.3%, p<0.001) yang lebih tinggi 
berbanding dengan lelaki. Analisis hasil kawasan bawah ROC lengkung 
menunjukkan 22 metabolit dikenalpasti sebagai penanda bio metabolit urin bagi 
penyakit sindrom metabolik dengan kawasan di bawah lengkung sekurang-
kurangnya 0.7. Model analisis regresi linear berganda menunjukan adiponektin berat 
molekul tinggi serum mempunyai korelasi secara negatif dengan ukur lilit pinggang 
(β=-0.07; p=0.001) dan jantina (β=-1.53; p<0.001) tetapi mempunyai korelasi secara 
positif dengan umur (β=0.05; p=0.004). Selain daripada itu, asid 3-ethyl-3-methyl-
tridecanoic (C16H32O2) urin mempunyai korelasi secara positif dengan tekanan darah 
sistolik (β=0.06; p=0.031). Metabolit urin ini tidak mempunyai korelasi dengan 
adiponektin berat molekul tinggi serum dalam model analisis regresi linear berganda 
tetapi mempunyai korelasi dalam analisis korelasi Spearman. Kajian ini dapat 
memberi petunjuk dan maklumat tambahan bagi mekanisma patogenik sindrom 
metabolik dalam kalangan OA. 
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THE ASSOCIATION OF METABOLIC SYNDROME RISK FACTORS 
WITH SERUM HIGH-MOLECULAR WEIGHT ADIPONECTIN AND 
URINARY METABOLITES AMONG THE ORANG ASLI IN MALAYSIA 
 
ABSTRACT 
 
Orang Asli (OA) are the indigenous people of Peninsular Malaysia. Overall, 
there are 18 subtribes of OA which are categorised under three main tribes namely 
Senoi, Proto Malay, and the Negrito. The association of metabolic syndrome (MetS) 
risk factors with serum high-molecular weight (HMW) adiponectin and urinary 
metabolites among OA tribes are scantly reported. The purpose of this study was to 
determine the association of MetS risk factors with serum HMW adiponectin and 
urinary metabolites among the OA population in Peninsular Malaysia. This cross-
sectional study was conducted according to the geographical locations of OA 
subtribes namely Che Wong, Kensiu, Semai, Orang Kanaq, Lanoh, and Bateq by 
simple random sampling method. The purposive and snow-ball sampling methods 
were used to select 185 respondents aged 18 years and above. The respondents were 
measured for their weight, height, waist circumference (WC), and blood pressure. 
Overnight fasting venous blood samples were analysed for lipid profiles, plasma 
glucose, and HMW adiponectin while urine samples were analysed for metabolite 
profiles using metabolomics approach. The overall prevalence of MetS was 29.7% 
(55/185). MetS prevalence was significantly higher in female (36.2%) compared to 
male (21.3%) respondents. MetS was also higher among the suburban Orang Kanaq 
(81.8%) and Kensiu (36.4%) subtribes and lower among rural Semai (23.8%) and 
Bateq (8.0%) subtribes (p<0.001). Females had significantly higher rates of high WC 
 xx 
 
(45.7% vs. 2.5%, p<0.001) and low HDL-C (69.5% vs. 31.3%, p<0.001) compared 
to males. Area under ROC curve (AUROC) analysis showed that 22 metabolites 
were determined as potential urinary metabolite biomarkers of MetS with area under 
the curve (AUC) of at least 0.7. Multiple linear regression models revealed that 
HMW adiponectin were negatively associated with WC (β=-0.07; p=0.001) and sex 
(β=-1.53; p<0.001) but positively associated with age (β=0.05; p=0.004). Besides, 
urinary 3-ethyl-3-methyl-tridecanoic acid (C16H32O2) level was positively associated 
with systolic blood pressure (β=0.06; p=0.031). This urinary metabolite was not 
associated with HMW adiponectin in multiple linear regression models but it was 
correlated with HMW adiponectin in Spearman correlation analysis. This study could 
provide clues and additional insight into the pathogenic mechanism of MetS among 
OA population.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background of the study 
 
Metabolic syndrome (MetS) is a constellation of cardiovascular disease (CVD) and 
type 2 diabetes mellitus (T2DM) risk factors namely hyperglycemia, elevated 
triglyceride (TG) levels, low high-density lipoprotein cholesterol (HDL-C) levels, 
raised blood pressure, and obesity (particularly central adiposity) (Alberti et al., 
2009). It can be defined using several definitions including World Health 
Organization (WHO) (Alberti and Zimmet, 1998), National Cholesterol Education 
Program Adult Treatment Panel III (NCEP ATP III) (NCEP ATP III, 2001), 
International Diabetes Federation (IDF) (Alberti et al., 2005) and the recently 
proposed Harmonized IDF criteria (Alberti et al., 2009).  
 
MetS is a complex disorder (Kassi et al., 2011) that associated with adverse 
health outcomes and become one of growing problem worldwide (Schlaich et al., 
2015). National Health and Nutrition Examination Survey (NHANES) data from 
2009 to 2010 indicated that the prevalence of MetS in United States was 22.9% 
based on Harmonized criteria (Beltran-Sanchez et al., 2013). Ten population based 
cohort studies in seven countries in Europe observed that the MetS rate in obese 
subjects ranged from 43% to 78%  and 24% to 65%  in men and women, respectively 
(Van Vliet-Ostaptchouk et al., 2014). 
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 The high prevalence of MetS not only affects developed countries but also 
some developing countries. Using the ATP III criteria which was same as Europe, a 
higher rate of MetS was observed among males (47.2%) compared to females 
(40.3%) in Saudi Arabia population (Al-Daghri et al., 2014). In a cross-sectional 
study in China, the prevalence of MetS was also higher in males (27.6%) than 
females (24.4%) based on Harmonized definition (Xu et al., 2014). Meanwhile in 
Malaysia, 42.5% of Malaysian adults were diagnosed with MetS where 43.9%, 
42.1%, and 51.9% were reported in Malay, Chinese, and Indian ethnic groups 
respectively (Mohamud et al., 2011). Moreover, the prevalence of MetS among 
Malaysians aged 15 years and older was higher among Indians (35.6%) compared to 
Indigenous Sarawakians (30.5%), Malays (26.4%) and Chinese (26.2%) (Rampal et 
al., 2012).  
 
Another study among Malay adults in Malaysia observed that the prevalence 
was reported around 31.9% on the basis of the modified NCEP ATP III criteria. (Chu 
and Moy, 2014). The prevalence rates of MetS in Malaysian T2DM patients were 
95.8%, 96.1%, 84.8%, and 97.7% according to the WHO, NCEP ATP III, IDF, and 
the Harmonized definitions respectively (Tan et al., 2013). The MetS is not only 
emerge among main population of Malaysia but also minority population which is 
Orang Asli (OA). A study conducted in 2010 reported that the prevalence of MetS 
among OA based on IDF criteria was 22.7% (Mohamud and Suraiami, 2010). 
 
Adiponectin is an adipokines that has association with the MetS risk factors. 
Low serum adiponectin concentrations are associated with multiple phenotypic traits 
of MetS including decreased insulin sensitivity, increased abdominal fat distribution, 
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and reduced HDL-C levels (Lara Castro et al., 2008). As a result, low circulating 
adiponectin level has been proposed as a biomarker for the MetS (Ryo et al., 2004; 
Trujillo and Scherer, 2005). Previous study indicated that high-molecular weight 
(HMW) adiponectin is the active form of the protein (Hara et al., 2006) and might be 
a more useful predictor than total adiponectin for assessing T2DM risk (Nakashima 
et al., 2006). According to Hara et al. (2006), the HMW ratio values has better 
predictive power than total adiponectin for prediction insulin resistance (IR) and 
MetS in humans (Hara et al., 2006). The HMW adiponectin complex is the most 
active form of adiponectin in depressing blood glucose levels in mice (Pajvani et al., 
2004). Moreover, HMW adiponectin that has antiatherogenic factors can prevent 
endothelial cells from apoptosis (Kobayashi et al., 2004). 
 
Besides adiponectin, there is association of MetS risk factors with 
endogenous metabolites. Urinary nicotinuric acid metabolite that correlated with 
MetS risk factors (Blood pressure, TG, and HDL-C), body mass index (BMI), total 
cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), glycated hemoglobin 
(HbA1c), and high-sensitivity C-reactive protein (hs-CRP) could represents a 
potential biomarker of MetS (Huang et al., 2013). The presence of metabolic risk 
factors including IR, obesity, high blood pressure, and dyslipidemia are significantly 
associated with serum metabolites such as branched-chain amino acids, other 
hydrophobic amino acids, tryptophan breakdown products, and nucleotide 
metabolites (Cheng et al., 2012).  
 
Bile acid (BA) metabolite in serum shows several positive and statistically 
significant correlations with single components of the MetS, namely BMI, glucose, 
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TG, homeostasis model assessment of insulin resistance (HOMA-IR), and HbA1c 
(Steiner et al., 2011). Further, branched-chain and aromatic amino acid metabolites 
in serum are linked with hyperglycemia in the general population study (Würtz et al., 
2012). The association of adiponectin can also be observed with urinary metabolite. 
Increased urinary tetrahydrometabolites (THM) not only correlated with 
dyslipidemia, IR, β cell dysfunction, weight, and WC but it also correlated with 
hypoadiponectinemia (Baudrand et al., 2011).  
 
There have been many health studies conducted on OA focusing on 
nutritional status (Haemamalar et al., 2010; Hian and Leng, 1998; Lin, 1988; Wong 
et al., 2015), parasitic infections (Al-Mekhlafi et al., 2013; Anuar et al., 2012), 
anemia (Al-Mekhlafi et al., 2008) and cardio-metabolic factors (Phipps et al., 2015). 
A study on MetS has been conducted among female OA and the focus was mainly on 
prevalence of the disease (Mohamud and Suraiami, 2010). To date, there is no study 
yet on the association of MetS risk factors with serum HMW adiponectin and urinary 
metabolites among the OA tribes in Peninsular Malaysia. 
  
1.2 Rationale of the study 
 
The large increase in incidence of obesity in both developed and developing 
countries has led to an escalating incidence of T2DM and CVD risk factors which 
collectively termed as MetS (Schlaich et al., 2015). The scant report on MetS 
prevalence among OA makes it impossible to provide trend of the disease in this 
population. However, this prevalence is expected to increase for the next decade as 
most OA population undergo resettlement programme which directly exposed them 
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to urbanised lifestyle. According to Kaur (2014), the increasing of the MetS are due 
to surplus energy intake, increasing obesity, urbanization, and sedentary life habits. 
Therefore it is important to search for greater insight about mechanisms contributing 
to the MetS development in this population.  
 
Adiponectin, a fat cell-secreted hormone is one of the factors contribute to the 
MetS development. Low circulating levels of adiponectin have been linked to several 
components of the MetS such as elevated WC, elevated TG, reduced HDL-C, and 
elevated blood pressure (Yun et al., 2011). Adiponectin that is abundantly expressed 
in adipose tissue has inverse association with IR (Mente et al., 2010), MetS (Kim et 
al., 2013), and T2DM (Jee et al., 2013; Ley et al., 2008).  
 
A detailed understanding of the MetS pathophysiology could be achived by 
using metabolomics technology. The measurement of small molecule metabolites 
provides insight into changes in chemical ‘‘signature’’ due to specific cellular 
processes and environmental exposures. Profiles of urinary metabolites  in individual 
that has MetS trait are useful in eluciding the potential roles of specific metabolites 
and the pathways underlying MetS disease. An earlier studies using metabolomics 
have identified urinary metabolite biomarkers and its mechanism for T2DM 
(Jankevics et al., 2009) and atherosclerosis (Zhang et al., 2009a). 
  
Many recent studies on the associations between MetS risk factors with  
HMW adiponectin and urinary metabolites come mainly from South America (von 
Frankenberg et al., 2014), Asia such as Japan (Saisho et al., 2013), Taiwan (Huang et 
al., 2013), and China (Yu et al., 2014). However, to the best of my knowledge there 
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are no studies and data available in Malaysia especially among OA population. 
Therefore, the study need to be established as ethnic-specific differences could 
modify the relationship between MetS risk factors with HMW adiponectin and 
urinary metabolites.  
 
1.3 Significance of the study 
 
This study provides an updated figure of health status and fundamental database for 
serum of adults OA population. Important parameters related to nutritional status and 
MetS was examined throughout the study including anthropometry and biochemical 
parameters such as glucose, HDL-C, TG, and HMW adiponectin levels. Besides, 
urinary metabolites from various classes such as fatty acids (FAs), amino acids 
(AAs), bile acids (BAs), and eicosanoids have been measured and profiled by using 
metabolomics technology. The profiling of metabolites provides curation database, 
novel biomarkers, and biochemical pathways for diagnosis and prognosis of MetS 
and related disorders in the study population. The discovery of urinary metabolite 
may add an useful and crucial information on MetS in molecular level. Its 
association with MetS risk factors and HMW adiponectin may provide greater 
pathophysiological understanding of disease. 
 
 In future, the biomarkers discovered through metabolomics technology could 
be used by doctors as a routine clinical practice to treat the patients. Furthermore, 
this study may help scientist and researchers to stimulate multiple research ideas 
especially in the aspect of epidemiology, public health, nutrition, metabolomics, and 
biomarker discovery towards Malaysian population specifically OA. 
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1.4 Objectives 
 
1.4.1 General objective 
 
To determine the association of MetS risk factors with serum HMW adiponectin and 
urinary metabolites among several subtribes of OA in Peninsular Malaysia.  
 
1.4.2 Specific objectives 
 
i. To assess the prevalence of MetS among the OA. 
ii. To assess individual risk factors of MetS among the OA. 
iii. To profile the urinary metabolites in MetS and non-MetS of OA. 
iv. To identify potential urinary metabolites of MetS. 
v. To investigate the association between MetS risk factors and HMW 
adiponectin. 
vi. To investigate the association between MetS risk factors and urinary 
metabolite. 
vii. To investigate the association between HMW adiponectin and urinary 
metabolite.  
 
1.5 Research questions 
 
i. What is the prevalence of MetS among the OA in Peninsular Malaysia? 
ii. What are the individual risk factors of MetS among the OA? 
iii. What are the urinary metabolite profiles in MetS and non-MetS of OA? 
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iv. What is the potential urinary metabolites of MetS? 
v. Is there any association between MetS risk factors and HMW 
adiponectin? 
vi. Is there any association between MetS risk factors and urinary metabolite? 
vii. Is there any association between HMW adiponectin and urinary 
metabolite? 
 
1.6 Null hypotheses  
 
i. There are no difference in the urinary metabolite profiles in MetS and 
non-MetS of OA tribes. 
ii. There are no association between MetS risk factors and HMW 
adiponectin. 
iii. There are no association between MetS risk factors and urinary 
metabolite. 
iv. There are no association between HMW adiponectin and urinary 
metabolite. 
 
1.7 Conceptual framework  
 
The conceptual framework of the study is presented in Figure 1.1. Poor dietary intake 
and physical inactivity are lifestyle factors that induce visceral fat accumulation and 
low plasma adiponectin level (hypoadiponectinemia). Besides, genetic factors such 
as I164T SNP is also associated with hypoadiponectinemia. Hypoadiponectinemia 
may lead to dysregulation of urinary metabolites and alterations in FAs and AAs 
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metabolism. Visceral adiposity will lead to hypoadiponectinemia and an increase in 
free fatty acid (FFA) concentrations (Cnop et al., 2003). These conditions enhance a 
cluster of T2DM, hypertension (elevated blood pressure), and dyslipidemia (high TG 
and low HDL-C) termed as MetS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR: Insulin resistance; T2DM: Type 2 diabetes mellitus; MetS: Metabolic syndrome 
 
Figure 1.1 Conceptual framework of the study  
 
(Adopted from Okamoto et al., 2006; current study) 
 
Lifestyle factors: 
 Poor dietary intake  
 Physical inactivity 
 
Visceral fat accumulation 
Hypoadiponectinemia 
 
IR 
T2DM Hypertension Dyslipidemia 
Dysregulation of metabolites 
 
Genetic factor 
Altered metabolism 
 
 
 
MetS 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Orang Asli 
 
OA is a Malay term which means original people are the indigenous inhabitants of 
Peninsular Malaysia (Khor and Zalilah, 2008). The Orang Asli Development 
Department (JAKOA) reported that the total population of OA in the year 2013 was 
178,197 (JAKOA, 2013) representing 0.6% of national population. The OA is 
classified into three main tribes namely Senoi, Proto Malay or Aboriginal Malay, and 
the Negrito. The categorisation of the tribes were based on morphology, culture, 
language, and geographical locations for the convenience of administration (Masron 
et al., 2013). The population distribution and characteristics of the study population 
is shown in Table 2.1. 
 
The Senoi is the largest OA tribe constituting about 55% (Khor and Zalilah, 
2008) of the population and scattered from the middle to northern part of the 
Peninsular Malaysia (Masron et al., 2013). The Senoi subtribes including Semai, Che 
Wong, Temiar, Jah Hut, Semoq Beri, and Mah Meri. The physical characteristics of 
Senoi are having variety of skin color and wavy hair, living as both hunter-gatherers 
and traders, and descend from an admixture of the Negrito and an East Asian 
population (Ang et al., 2012). Senoi speak Austro-Asiatic languages of the Mon-
Khmer subgroup, indicating their ancient connection with the mainland Southeast 
Asia (Nicholas, 2000).  
 
 11 
 
Table 2.1 Population distribution and characteristics of the study population of 
Orang Asli subtribe 
Tribe Subtribe Population of  
2013
a 
Name of the area Location 
type 
Negrito  5,009   
 Kensiu
b 
237 Kg. Lubuk Legong, 
Baling, Kedah 
Suburban 
 Kintak 194   
 Lanoh
b
 382 Kg. Air Bah, 
Lenggong, Perak 
Rural 
 Jahai 2,387   
 Mendriq 362   
 Beteq
b
 1,447 Kg. Aring 5, Gua 
Musang Kelantan 
Rural 
Senoi  97,856   
 Temiar 31,038   
 Semai
b
 51,437 Pos Tual, Kuala 
Lipis, Pahang 
Rural 
 Semoq Beri 5,313   
 Che Wong
b
 651 Kg. Sungai Enggang, 
Lanchang, Pahang 
Suburban 
 Jah Hut 5,618   
 Mah Meri 3,799   
Proto 
Malay 
 75,332   
 Temuan 27,590   
 Semelai 7,727   
 Jakun 34,722   
 Orang Kanaq
b
 148 Kg. Sungai Selangi, 
Kota Tinggi,  Johor 
Suburban 
 Orang Kuala 3,525   
 Orang Seletar 1,620   
Total  178,197   
a
Data obtained from the Orang Asli Museum, Gombak, viewed 15 April 2015. 
b 
Study population 
 
The second largest tribe of OA is Proto Malay or Aboriginal Malay 
constituting around 42% of the population (Khor and Zalilah, 2008). They can be 
found mainly in the middle and southern states of Pahang, Johor, Negeri Sembilan, 
and Selangor (Khor and Zalilah, 2008) and are similar to Deutero-Malays from the 
morphological aspect, culture, and languages (Lim et al., 2010). Proto Malays 
consist of Jakun, Temuan, Semelai, Orang Kanaq, Orang Seletar, and Orang Kuala. 
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The migration of Proto Malay from Yunnan to Peninsular Malaysia happened around 
4,000 years ago after the arrival of Negrito and Senois (Fix, 1995). The Proto Malay, 
who work as farmer-traders have a lighter skin color and straight hair (Fix, 1995). 
 
The Negrito is the least tribes which has approximately 3% of the population 
(Khor and Zalilah, 2008). The settlements of this tribe are isolated and scattered but 
mostly distributed in the northern and central region of the Peninsular Malaysia 
(Masron et al., 2013). They can be classified into six subtribes, mainly Bateq, 
Kensiu, Kintaq, Jahai, Lanoh, and Mendriq. The Negrito is the earliest OA tribes 
arrived in the Peninsular Malaysia which was around 25, 000 years ago (Masron et 
al., 2013). The Negrito population is the first occupants of South-East Asia, has dark 
skin, curly hair, and live as hunter-gatherers (Ang et al., 2012). Generally, the Jahai 
subtribe is physically similar to negro in Africa, Andaman islanders, and Aeta in the 
Philippines (JAKOA, 2015b). The distribution map of the OA subtribes is shown in 
Figure 2.1.  
 
The government of Malaysia through JAKOA had commenced an inclusive 
development programmes since 1954 as efforts to transform and develop the OA 
community (Yahaya et al., 2011). Three main development programme by  JAKOA 
includes structured settlements development, economic development, and social 
development (JAKOA, 2015a). One of the development programmes that has been 
implemented for remote and scattered settlement of the OA community was The 
Resettlement Scheme or RPS (Kamaruddin, 2008). This scheme provided basic 
facilities including housing, kindergarten, community halls, electricity, water, and 
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access roads and currently 17 RPS has been implemented and benefited 3,015 
families (Kamaruddin, 2008).  
 
Figure 2.1   Distribution map of the Orang Asli subtribes in Peninsular Malaysia 
(Source: Center for Orang Asli Concerns, 2015) 
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Based on JAKOA record, until 31 Disember 2010, there are 852 OA villages 
that has been classified into rural, suburban, and urban (Yahaya et al., 2011). These 
classifications were based on location, phase of economic development, and basic 
facilities and infrastructures (Yahaya et al., 2011). The classification of OA village is 
shown in Table 2.2. 
 
Table 2.2 Classification of Orang Asli village 
Category Number of village Criteria 
Rural 327 a. Can be reached by dirt roads, trail roads, 
    or waterways 
b. Do not have access to clean water, 24    
    hours electricity, and other basic 
    amenities 
c. Do not have fix incomes  
Suburban 519 a. Near with Malay village 
b. Can be reached by paved roads 
c. Have basic facilities, clean water  
    supply, 24 hours electricity supply  
d. Have land development projects and  
    fix incomes  
Urban 6 a. Has a complete facilities 
b. There are no land development projects 
(Source: Yahaya et al., 2011) 
 
2.2 Nutritional status 
 
Nutritional status refer to the person health as it relates to how well diet meets that 
person’s individual nutrient requirements (Mcguire and Beerman, 2007). Generally, 
the nutritional status can be assessed using four components namely anthropometric 
measurements (height, weight, circumferences, and body composition), biochemical 
measurements (blood and urine), clinical assessment (medical history and physical 
examination), and dietary assessment (24-hour recall method, food frequency 
questionnaire, and diet record) (Mcguire and Beerman, 2007). Anthropometric 
measurements were widely used because it can be easily performed with appropriate 
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training, does not require sophisticated machine or equipment, can be performed in 
field settings, and economical  (Yusof et al., 2007). 
 
Globally, the overweight and obesity have affected both developed and 
developing countries, men and women, adults and children (Yatsuya et al., 2014) and 
the prevalence of this epidemic is on the rise. The survey conducted on more than 
100 countries around the world observed that the proportions of overweight and 
obesity increased between the year 1980 and 2013 from 28.8% to 36.9% in males 
and from 29.8% to 38.0% in females (Ng et al., 2014). Ng et al. (2014) also reported 
that the estimated rate of obesity exceeded 50% in male in Tonga and female in 
Kuwait, Kiribati, the Federated States of Micronesia, Libya, Qatar, Tonga, and 
Samoa. 
 
The findings of National Health and Morbidity Survey (NHMS) 2011 
indicated that the rate of overweight and obesity (29.4% and 15.1%) among adults 
Malaysian was comparable to that reported in NHMS III 2006 (28.6% and 14.0%) 
based on the WHO (1998) classification (IPH, 2011). However, more than 60% of 
Malaysian adults were estimated pre-obese and obese according to the Malaysian 
Clinical Practice Guidelines on Management of Obesity (2004) classification (IPH, 
2011). Another study in 2011 observed that the rate of overweight and obesity 
among adult Malaysians were 33.6% and 19.5%  respectively (Wan Mohamud et al., 
2011). The updated in NHMS 2015 indicated that the national prevalence of 
overweight and obesity were 30.0% and 17.7% respectively according to the WHO 
(1998) classifications while the rate of overweight and obesity were 33.4% and 30.6% 
respectively according to the Malaysian Clinical Practice Guidelines of Obesity 
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(2004) classifications (IPH, 2015).  Besides, the national prevalence of abdominal 
obesity or central obesity was 48.6% according to the International Diabetes 
Institute/Western Pacific World Health Organization/International Association for 
the study of Obesity/International Obesity Task Force (WHO/IASO/IOTF, 2000) 
(IPH, 2015). The emergence of obesity is believed to cause a number of risk factors 
for T2DM and cardiovascular diseases (CVDs) known as MetS. Underweight and 
obesity epidemics, particularly higher levels of obesity were found associated with 
increased mortality among American adults (Flegal et al., 2005). 
 
2.2.1 Metabolic syndrome 
 
MetS is defined as a constellation of interconnected physiological, biochemical, 
clinical, and metabolic factors that directly augments the risk of CVD, T2DM, and 
all cause mortality (Kaur, 2014). Overweight, obesity, and physical inactivity are 
modifiable factors that closely linked with MetS (Chu and Moy, 2014). Many 
international organizations and expert groups had attempted to propose the 
definitions of MetS.  
 
The first definition of MetS by WHO was proposed in 1998 which highlight 
IR as the major underlying risk factor and required evidence of IR for diagnosis 
(Alberti and Zimmet, 1998). A diagnosis of the syndrome by WHO criteria could 
thus be made on the basis of several markers of IR plus two additional risk factors, 
including obesity, hypertension, reduced HDL-C level, high TG level, or 
microalbuminuria (Alberti and Zimmet, 1998). In 2011, the other definition of MetS 
was proposed by NCEP ATP III (NCEP ATP III, 2001). NCEP ATP III criteria did 
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not require demonstration of IR and no single factor was required for diagnosis 
(NCEP ATP III, 2001). However, NCEP ATP III made the presence of 3 of the 5 
factors including elevated WC (highly correlated with IR), reduced HDL-C, elevated 
TG, elevated fasting glucose (impared fasting glucose or T2DM), and elevated blood 
pressure as the basis for establishing the diagnosis (NCEP ATP III, 2001). This 
definition was presented as part of an educational programme for the prevention of 
coronary heart disease (CHD) (Alberti et al., 2006). 
 
In 2005, another definition of MetS was proposed by IDF (Alberti et al., 2005) 
in an effort to define the syndrome more precisely and therefore it could be used by 
different clinical and research groups (Kassi et al., 2011). IDF introduced abdominal 
obesity as a prerequisite of the diagnosis plus any two of risk factors (elevated WC, 
reduced HDL-C, elevated TG, elevated fasting plasma glucose, and elevated blood 
pressure) as the basis for establishing the diagnosis (Alberti et al., 2005). Ethnic-
specific values for WC is shown in Table 2.3. The IDF guidelines stressed adoption 
of different values for WC in different ethnic groups based on the relationship of WC 
either to the other MetS components or to longer-term outcome studies such as those 
on the risk of  T2DM and CVD (Alberti et al., 2009). 
 
In 2009, IDF and American Heart Association/National Heart, Lung, and 
Blood Institute (AHA/NHLBI) representatives held discussions to resolve the 
remaining differences between definitions of MetS and to unify the criteria (Alberti 
et al., 2009). This latest harmonized definition proposed that MetS was diagnosed by 
the presence of any 3 of 5 risk factors which abdominal obesity is not a prerequisite 
risk factor (Alberti et al., 2009). The definitions of MetS by organization is shown in 
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Table 2.4. In Harmonized definition, the population and country-specific values for 
WC was used (Alberti et al., 2009). According to Alberti et al. (2009), the IDF cut 
points of WC were recommended to be used for non-Europeans and either the IDF or 
AHA/NHLBI cut points were used for European origin. Table 2.5 presents WC 
threshold by several organization. 
 
Table 2.3 Ethnic-specific cut points for waist circumference by International 
Diabetes Federation organization 
Ethnic group
a
 WC (as measure of central obesity) 
Europids Men ≥94 cm 
Women  ≥80 cm 
South Asians Men ≥90 cm 
Women  ≥80 cm 
Chinese Men ≥90 cm 
Women  ≥80 cm 
Japanese Men ≥85 cm 
Women ≥90 cm 
Ethnic south and central 
Americans 
Use south Asian recommendations until more 
specific data are available 
Sub-Saharan Africans Use European data until more specific data are 
available 
Eastern  Mediterranean  and  
Middle East (Arab) 
Use European data until more specific data are 
available 
WC: Waist circumference 
a
Ethnicity should be basis for classification, not country of residence 
 
  (Source: Alberti et al., 2005) 
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Table 2.4 Definitions of metabolic syndrome by organization 
Risk factors WHO (1998) 
NCEP ATP 
III (2001) 
IDF (2005) 
Harmonized 
IDF (2009) 
Obesity (BMI) or 
abdominal obesity 
(WC) 
 
BMI >30kg/ 
m
2 
and/or 
WHR > 0.90 
(M), > 0.85 
(F) 
WC  
M >102 cm, 
F >88 cm 
WC (Ethnic- 
specific) 
WC 
(Population- 
and 
country-
specific )
a
 
High BP 
(Systolic/ 
Diastolic) 
≥ 160/90 
mmHg  
≥130/85 
mmHg 
 
≥130/85 
mmHg or on 
Rx 
Systolic ≥ 
130 and/or  
diastolic ≥ 85 
mmHg or on 
Rx 
High FPG  IGT or DM 
and/or IR 
≥ 6.1 mmol/L 
or DM 
≥5.6 mmol/L 
or DM 
≥5.6 mmol/L 
or DM or on 
Rx 
Microalbuminuria  UAE ≥ 20 
µg/min or 
ACR ≥ 20 
mg/g 
- - - 
Elevated TG ≥ 1.7 mmol/L ≥1.7 mmol/L > 1.7 mmol/L ≥1.7 mmol/L 
or on Rx 
Reduced HDL-C <0.9 mmol/L 
(M), < 1.0 (F) 
<1.0 mmol/L 
(M), <1.3 (F) 
<1.03 
mmol/L 
(M), <1.29 
(F) 
<1.0 mmol/L 
(M), <1.3 (F) 
or on Rx 
MetS IGT or DM 
and/or IR + 
any 2 or more 
RF 
At least 3 RF WC + 2 more 
RF 
At least 3 RF 
WHO: World Health Organization; NCEP ATP III: National Cholesterol Education 
Program Adult Treatment Panel III; IDF: International Diabetes Federation; BMI: 
Body Mass Index; WHR: Waist hip ratio; WC: Waist circumference; BP: Blood 
pressure; FPG: Fasting plasma glucose; UAE: Urinary albumin excretion; ACR: 
Albumin/creatinine ratio; TG: Triglyceride; HDL-C: High-density lipoprotein 
cholesterol; Rx: On medication; IGT: Impaired glucose tolerance; DM: Diabetes 
mellitus; IR: Insulin resistance; MetS: Metabolic syndrome; M: Male; F: Female; 
RF: Risk factors 
a
It is recommended that the IDF cut points be used for non-Europeans and either the  
IDF or AHA/NHLBI cut points used for European origin until more data are 
available. 
 
(Source: Alberti et al., 2009; Alberti et al., 2005; Alberti and Zimmet, 1998; NCEP 
ATP III, 2001) 
 
 
 
 
 20 
 
Table 2.5 Current recommended cut points for waist circumference by  
organization 
  WC cut points 
Population Organization  Men Women 
Europid IDF ≥94 cm ≥80 cm 
Caucasian WHO ≥94 cm 
(increased risk) 
≥102 cm (still 
higher risk) 
≥80 cm 
(increased risk) 
≥88 cm (still 
higher risk) 
United States AHA/NHLBI 
(ATP III) 
≥102 cm ≥88 cm 
Canada Health Canada ≥102 cm ≥88 cm 
European European 
Cardiovascular 
Society 
≥102 cm ≥88 cm 
Asian (including 
Japanese) 
IDF ≥90 cm ≥80 cm 
Asian WHO ≥90 cm ≥80 cm 
Japanese Japanese Obesity 
Society 
≥85 cm ≥90 cm 
China Cooperative Task 
Force 
≥85 cm ≥80 cm 
Middle East, 
Mediterranean 
IDF ≥94 cm ≥80 cm 
Sub-Saharan African IDF ≥94 cm ≥80 cm 
Ethnic Central and 
South American 
IDF ≥90 cm ≥80 cm 
WC: Waist circumference; IDF: International Diabetes Federation; WHO: World 
Health Organization; AHA/NHLBI: American Heart Association/National Heart, 
Lung, and Blood Institute; ATP III : Adult Treatment Panel III 
 
(Source: Alberti et al., 2009) 
 
2.3 Adipokines 
 
Adipose tissue can be classified into two major types namely white adipose tissue 
(WAT) and brown adipose tissue (Fantuzzi, 2005). The distribution of brown adipose 
tissue in humans are in cervical-supraclavicular area and the shape of this tissue is 
polygonal with multi-ocular lipid droplets (Kwon and Pessin, 2013). It can be found 
in newborn humans but almost absent in adults (Coelho et al., 2013). The function of 
brown adipose tissue (BAT) is to dissipate energy and generate heat (Berry et al., 
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2013). WAT is located throughout the body (Kwon and Pessin, 2013). Subcutaneous 
and visceral adipose tissues are the major adipocyte depots of WAT with additional 
adipose depots distributed at various organs including heart, lung, and kidney (Kwon 
and Pessin, 2013). WAT is composed of variety cell types such as adipocytes, 
macrophages, lymphocytes, fibroblasts, and endothelial cells (Kwon and Pessin, 
2013). It is designed as energy storage (Berry et al., 2013) and endocrine organ 
because of its capacity to secrete hormones and cytokines (Vázquez-Vela et al., 
2008). 
 
Adipokines are proteins that produced mainly by adipocytes (Fantuzzi, 2005). 
Subcutaneous or visceral adipose tissue play a role in secretion of adipokines (Kwon 
and Pessin, 2013). Adipokines can act centrally to regulate appetite and energy 
expenditure, and peripherally affect insulin sensitivity, oxidative capacity, and lipid 
uptake (de Oliveira Leal and Mafra, 2013). The release of adipokine by either 
adipocytes or adipose tissue macrophages could induce a low-grade chronic 
inflammatory state that play a central role in obesity related cardiovascular 
complications and IR (Antuna-Puente et al., 2008). The inflammatory functions of 
adipokines are responsible for mediating obesity-induced insulin resistance (Kwon 
and Pessin, 2013). On this point, adipokines are categorized as pro- and anti-
inflammatory adipokines according to their effects on inflammatory responses in 
adipose tissues (Kwon and Pessin, 2013). 
 
Example of pro-inflammatory adipokines are leptin, interleukin-6 (IL-6), 
tumor necrosis factor-α (TNF-α), retinol binding protein 4 (RBP4), resistin, CC-
chemokine ligand 2 (CCL2), CC-chemokine receptor type 5 (CCR5), angiopoietin-
 22 
 
like protein 2 (ANGPTL2), and chemerin while anti-inflammatory adipokines are 
adiponectin, secreted frizzled-related protein 5, visceral adipose tissue-derived serine 
protease inhibitor, omentin-1, and apelin (Kwon and Pessin, 2013). Figure 2.2 shows 
the adipokines that most clearly associated with obesity and MetS. 
 
 
ACE: Angiotensinogen-converting enzyme; MCP-1: Monocyte chemoattractant 
protein-1; PAI-1: Plasminogen activator inhibitor-1;  RBP4: Retinol binding protein 
4; SAA: Serum amyloid A; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-α; 
VEGF: Vascular endothelial growth factor  
 
Figure 2.2 Different type of adipokines released by the adipose tissue that 
associated with obesity and metabolic syndrome 
 
(Source: Gustafson et al., 2007) 
 
Of these adipokines, leptin is widely studied (Gustafson et al., 2007) and has 
been the most thoroughly investigated (Avram et al., 2005). Leptin is positively 
related to adipocyte size and obesity which is in contrast to adiponectin (Gustafson et 
al., 2007). The metabolic function of leptin including repression of food intake, 
promotion of energy expenditure, stimulation of FA oxidation in liver, pancreas, and 
skeletal muscle, modulation of hepatic gluconeogenesis, and modulation of 
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pancreatic β cell function (Rabe et al., 2008). TNF-α and IL-6 are important 
inflammatory molecules associated with obesity and IR (Gustafson et al., 2007) 
which functioning as modulation of hepatic and skeletal muscle insulin signalling 
(Rabe et al., 2008). Adiponectin is one of the most widely studied adipokine 
(Gustafson et al., 2007; Turer and Scherer, 2012) and highly expressed by adipocyte 
cells with strong anti-inflammatory properties (Kwon and Pessin, 2013). Adiponectin 
(microgram per milliliter) circulates at the highest levels as compared to leptin 
(nanograms per millilitre) (Fantuzzi, 2005). It is a key mediator of systemic insulin 
sensitivity and glucose homeostasis (Turer and Scherer, 2012). These effects can be 
achieved by a diverse set of effects on several important targets including liver, 
pancreas, cardiac myocytes, the immune system, and even the adipose tissue itself 
(Turer and Scherer, 2012). 
 
2.3.1 Adiponectin 
 
Adiponectin was discovered during gene-expression profiling of human adipose 
tissue conducted by the human complementary deoxyribonucleic acid (cDNA) 
project (Di Chiara et al., 2011). It is encoded by the ADIPOQ gene that can modulate 
insulin sensitivity and glucose homeostasis (Schwarz et al., 2006). It is involved in 
regulating glucose levels as well as fatty acid (FA) breakdown (Al-Braich et al., 
2014). According to Kadowaki et al. (2006), adiponectin is an adipokine or 
adipocytokines that is specifically and abundantly expressed in adipose tissue and 
directly sensitizes the body to insulin (Kadowaki et al., 2006). It possesses anti-
diabetic, anti-atherogenic, and anti-inflammatory properties (Matsuzawa, 2010). 
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2.3.1 (a) Structure and circulating levels 
 
Full-length adiponectin contains 244 amino acids, a signal peptide, a collagen like 
domain at its N-terminus and a globular domain at its C-terminus, which shares 
sequence similarities with collagens X and VIII as well as complement factor C1q 
(Okamoto et al., 2006). It requires post-translational modifications for biological 
activity (hydroxylation and glycosylation) (Wang et al., 2002).  
 
Adiponectin circulates in plasma as a low-molecular weight (LMW) trimer 
(~90kDa), a middle-molecular weight (MMW) hexamer (~180 kDa), and high-
molecular weight (HMW) 12- to 18-mer (400 kDa) and these forms were postulated 
to differ in biologic activity (Pajvani et al., 2003; Waki et al., 2003; Wang et al., 
2006). A smaller form of adiponectin consisted of globular domain also exists in 
plasma in a very small amount (Fruebis et al., 2001). Figure 2.3 shows the domains 
and structure of adiponectin. Adiponectin is relatively abundant in plasma with a 
concentration range of 2-10 µg/ml (Arita et al., 1999). Matsuzawa (2010) reported 
that the average concentrations of adiponectin in human plasma are extremely high 
up to 5-10 μg/ml. 
 
